Top of page

Experience

To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.

Filters

Antengene HK$2.79 billion IPO

Davis Polk advised Antengene Corporation Limited in connection with its initial public offering and listing on the Hong Kong Stock Exchange and an international offering in reliance on Rule…

RemeGen HK$4 billion Hong Kong IPO

Davis Polk advised the underwriters in the initial public offering of RemeGen Co., Ltd. on the Hong Kong Stock Exchange and an international offering and listing in reliance on Rule 144A…

JW (Cayman) Therapeutics HK$2.33 billion Hong Kong IPO

Davis Polk advised the underwriters in the initial public offering of JW (Cayman) Therapeutics Co. Ltd on the Hong Kong Stock Exchange and an international offering and listing in reliance…

Shui On Land $500 million high-yield notes offering

Davis Polk advised the joint lead managers in connection with a $500 million Regulation S bonds offering by Shui On Development (Holding) Limited of its 6.150% senior notes due 2024…

Innovent Biologics HK$4.65 billion share placement

Davis Polk advised the sole placing agent for the placement of 56,200,000 new shares and 36,800,000 existing shares in Innovent Biologics, Inc., for an aggregate consideration of…
Back to top